About 4,630 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  1,642 results

Home-based exercise in autoimmune myasthenia gravis: A randomized controlled trial.
Neuromuscular Disorders : NMD; Birnbaum S, Porcher R et. al.

Jul 26th, 2021 - The tolerance of exercise and its effects on quality of life in myasthenia gravis are not currently backed up by strong evidence. The aim of this study was to determine whether exercise as an adjunct therapy is well tolerated and can improve healt...

Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis.
Neuromuscular Disorders : NMD; Andersen LK, Aadahl M et. al.

Jul 25th, 2021 - The objective of the study was to examine the association between fatigue (measured by the Multidimensional Fatigue Inventory; MFI-20) and physical activity (measured by the Saltin-Grimby Physical Activity Level Scale; SGPALS) in a large cohort of...

Absence of Association between Previous Mycoplasma pneumoniae Infection and Subsequent ...
International Journal of Environmental Research and Publi... Chen K, Wei JC et. al.

Jul 24th, 2021 - Mycoplasma pneumoniae (M. pneumoniae) is not only one of the most common pathogenic bacteria for respiratory infection but also a trigger for many autoimmune diseases. Its infection process shared many similarities with the pathogenesis of myasthe...

Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal o...
BMJ Case Reports; Muralidhar Reddy Y, B SK et. al.

Jul 22nd, 2021 - Several case reports of COVID-19 in patients with myasthenia gravis (MG) have been documented. However, new-onset autoimmune MG following COVID-19 has been reported very rarely. We report one such case here. A 65-year-old man presented to us with ...

Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital o...
BMJ Open; Berrih-Aknin S, Claeys KG et. al.

Jul 21st, 2021 - Myasthenia gravis (MG) is a rare, chronic, autoimmune disease, mediated by immunoglobulin G antibodies, which causes debilitating muscle weakness. As with most rare diseases, there is little patient-reported data with which to understand and addre...

see more →

Guidelines  4 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 4th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

The Association of British Neurologists' myasthenia gravis guidelines.
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 9th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critical...
Critical Care Medicine; Murray MJ, DeBlock H et. al.

Oct 18th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...

International consensus guidance for management of myasthenia gravis: Executive summary.
Neurology Sanders DB, Wolfe GI et. al.

Jun 30th, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

see more →

Drugs  54 results see all →

Clinicaltrials.gov  33 results

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Apr 23rd, 2020 - The study consisted of a single dose course of IGIV-C treatment followed by 28-days of post-infusion assessments. The total duration of study participation for each subject was up to 28 ± 2 days. Approximately 50 subjects, ages 18 or greater, were...

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Mar 29th, 2020 - This study consists of 2 phases: IGIV-C Run-in Phase and Corticosteroid Tapering/IGIV-C Maintenance Phase. In the Run-in Phase, subjects will receive a total of 3 doses of IGIV-C (1 loading dose of 2 g/kg and 2 maintenance doses of 1 g/kg) while m...

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Jan 26th, 2020 - This is a randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Sep 23rd, 2019 - This study is a Phase II, double-blind, randomized, three-way crossover, placebo-controlled, PD study of CK-2017357 in patients with generalized MG on standard therapy. 36 to 78 patients will be randomized at approximately 15 study centers to one ...

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Jul 24th, 2019 - The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).

see more →

News  108 results

Fast Five Quiz: Refresh and Test Your Knowledge of Myasthenia Gravis

Jul 5th, 2021 - Myasthenia gravis (MG) is a relatively rare autoimmune disorder in which antibodies form against nicotinic acetylcholine (ACh) postsynaptic receptors at the neuromuscular junction of the skeletal muscles. It is a type II hypersensitivity immune re...

Potential First-in-Class, Targeted Therapy for Myasthenia Gravis

Jun 16th, 2021 - Efgartigimod (argenx) is an effective and well-tolerated therapy for patients with generalized myasthenia gravis (gMG), new research suggests. Results from the phase 3, randomized, placebo-controlled ADAPT trial showed that reduction in disease bu...

New Steroid Dosing Regimen for Myasthenia Gravis

Feb 15th, 2021 - The findings of a new randomized trial support the rapid tapering of prednisone in patients with generalized myasthenia gravis requiring combined corticosteroid and azathioprine therapy. The trial showed that the conventional slow tapering regimen...

Ocular Side Effects Possible With Checkpoint Inhibitors

Nov 26th, 2020 - NEW YORK (Reuters Health) - People who use immune-checkpoint inhibitors have an increased risk of noninfectious uveitis and myasthenia gravis, according to a database study. Several case series have reported ocular side effects of checkpoint inhib...

COVID-19 Linked to Development of Myasthenia Gravis

Aug 18th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Myasthenia gravis should be added to the growing list of potential neurological sequelae associated with COVID-19, new research suggests. Clinicia...

see more →

Patient Education  11 results see all →